This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Type 2 Diabetes Mellitus as Catalyst for Alzheimer...
Clinical trial

Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease (DIACEA)

Read time: 1 mins
Last updated:1st May 2015

In recent years, it has been observed that the type 2 diabetic patients (DM-2) have an increased risk of developing dementia, both vascular and Alzheimer's disease (AD). The term mild cognitive impairment (MCI) describes a transition state between normal cognitive function and dementia. The annual rate of conversion to dementia in MCI patients is around 15% in the general population, regardless of the presence or absence of diabetes. At present it is not possible to identify which patients with MCI are most likely to progress to AD. On this basis, the main objective of this study is to evaluate whether the presence of diabetes and or the presence of its related genes favors the conversion of MCI to AD.

 

Study Type: Observational [Patient Registry]

Observational Model: Case Control

Target Follow-Up Duration: 2 Years

Official Title: Type 2 Diabetes Mellitus as Accelerator for the Progression to Alzheimer's Disease in Patients With Mild Cognitive Impairment

Estimated Enrollment: 220

Study Start Date: May 2015

Estimated Study Completion Date: May 2016

Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)

 

Arms:

T2D-MCI
110 MCI subjects with type 2 diabetes. There is a retrospectiv observational study. No intervention will be performed.

 

nonT2D-MCI
110 MCI subjects without diabetes. There is a retrospectiv observational study. No intervention will be performed.

Category Value
Study start date 2015-05-01

View full details